Skip to main content
. 2021 May 6;13(5):843. doi: 10.3390/v13050843

Figure 1.

Figure 1

The HIV-1 entry process and FDA-approved drugs inhibiting this process. The HIV-1 entry is a complex process involving many steps. Four FDA-approved drugs targeting different steps of the HIV-1 entry are shown. These include fostemsavir that blocks CD4 binding (attachment inhibitor class), ibalizumab targeting the domain II of CD4 receptor (post-attachment inhibitor class), maraviroc binding to CCR5 coreceptor (CCR5 antagonist class), and enfuvirtide binding to gp41 (fusion inhibitor class). Figure was prepared in BioRender.